News and Events
In April 2026, Entirety announced a new Medical Advisory Board in support of the company’s Orthopedic Extremities applications. These KOL surgeons will guide clinical strategy and product development as the company advances its Curasorb platform, building upon Entirety's initial CMF Advisors and reflecting the platform's versatility across surgical specialities and ortho fixation applications.
February 2026 Press Release:
Entirety Biomedical announces the close of a $1.2 Million (USD) Seed Financing Round to advance its absorbable metal implants for orthopedic fixation.
Following a July 2025 corporate rebrand, we are delighted to announce that we are now doing business as Entirety Biomedical!
Click to read more about the change and our exciting future plans.
Magsorbeo Biomedical, now doing business as Entirety Biomedical, was officially selected for the 2025 MedTech Innovator accelerator in the American Society of Plastic Surgeons (ASPS) Specialty Track. We are honored to have been chosen to participate with this exclusive group of the top exciting emerging med tech companies.
